ARTICLE SUMMARY:
But so far only one device, a vagus nerve stimulator for stroke patients, is a shoo-in to get a new Medicare hospital inpatient new technology add-on payment (NTAP) next year. Other products will qualify for the bonus if they can win FDA authorization in time or meet other CMS thresholds.
Eight new devices, primarily orthopedic and neuromodulation products, have so far passed CMS muster to gain extra reimbursement to cover their costs for inpatient procedures starting next fiscal year. But most of those are still waiting for FDA authorization, which needs to be granted by July 1 to qualify for the payments. Another four devices are also still candidates for new FY 2023 new technology add-on payments (NTAPs), but still have a case to make to the Medicare agency, according to CMS’s FY 2023 Hospital Inpatient Prospective Payment System (IPPS) proposed rule. (See table.)
